“Six-and-twelve” score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort

Table 3 Kaplan-Meier survival analysis according to “Six-and-twelve” score and other systems in the multicenter French cohort (n = 324)

Scoring/stage systems	OS [95%CI], mo	P value (log-rank)	Sidak1	Hazard ratio [95%CI]	P value
“6&12” score		< 0.0001
sum ≤ 6 (n = 154)	31 [27-35]		Ref	Ref
sum > 6 ≤ 12 (n = 163)	20 [17-24]		0.0009	1.55 [1.21-1.99]	0.0005
sum > 12 (n = 7)	15 [5-19]		< 0.0001	3.80 [1.76-8.21]	0.0007
BCLC staging		< 0.0001
A (n = 145)	35 [29-38]		NR	Ref
B (n = 179)	19 [17-23]		NR	1.88 [1.47-2.41]	< 0.0001
NIACE score		< 0.0001
≤ 1 (n = 168)	35 [28-36]		Ref	Ref
1.5 - 3 (n= 134)	20 [16-23]		< 0.0001	1.92 [1.49-2.48]	< 0.0001
> 3 (n = 22)	11 [5-16]		< 0.0001	6.23 [3.87-10.02]	< 0.0001
Child-Pugh class		0.0003
A (n = 249)	27 [25-31]		NR	Ref
B (n = 75)	21 [15-24]		NR	1.66 [1.26-2.19]	0.0003
ALBI grade		0.0029
Grade 1 (n = 64)	35 [25-43]		Ref	Ref
Grade 2 (n = 230)	26 [22-28]		0.1228	1.50 [1.06-2.11]	0.0216
Grade 3 (n = 30)	16 [12-24]		0.0016	2.30 [1.41-3.75]	0.0009

¹Sidak test for multiple comparisons. OS: Overall Survival; CI: Confidence Interval; “6&12”: “Six-and-twelve”; Ref: Reference; BCLC: Barcelona Clinic Liver Cancer; NIACE: Tumor nodularity, infiltrative nature of the tumor, alpha-fetoprotein, child-pugh class, performance status; ALBI: Albumin-Bilirubin.